TargetBeta
GPC3
glypican 3 · also OCI-5, SGBS, SGBS1, SGB · Glypicans
10 programs in company-led studies act on GPC3, from 10 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033rule | BeOne Medicines | phase 3 | 33 running | TNFRSF9 | NCIt |
| GPC3-targeted Plasmid DNA Vaccine NWRD06rule | Newish Biotech (Wuxi) | phase 2 | 22 running | – | NCIt |
| Actinium Ac 225 GPC3-targeted Peptide RYZ801 | Bristol-Myers Squibb | phase 2 | 11 running | – | a judged reading |
| Anti-GPC3 T Cell-engaging Antibody AZD9793 | AstraZeneca | phase 2 | 11 running | CD3E, CD8A | a judged reading |
| codrituzumab | Hoffmann-La Roche | phase 2 | 30 running | – | a judged reading |
| ACE723rule | Acepodia Biotech | phase 1 | 11 running | – | the studies' text |
| Actinium Ac 225 GPC3-targeted Antibody Conjugate BAY 3547926rule | Bayer | phase 1 | 11 running | – | NCIt |
| Anti-GPC3 Antibody-drug Conjugate ABBV-324 | AbbVie | phase 1 | 11 running | – | a judged reading |
| Anti-GPC3 Antibody-drug Conjugate ZW251rule | Zymeworks | phase 1 | 11 running | – | NCIt |
| TQB6426rule | Sino Biopharmaceutical | phase 1 | 11 running | – | the studies' text |
Conditions their studies are in
- Carcinoma, Hepatocellular, 8 programs
- Liver Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 31, 2027Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033 · BeOne Medicines · phase 3 · NCT06427941
- Jun 30, 2027Anti-GPC3 T Cell-engaging Antibody AZD9793 · AstraZeneca · phase 2 · NCT06795022
- Aug 2027TQB6426 · Sino Biopharmaceutical · phase 1 · NCT07730190
- Sep 2027Anti-GPC3 Antibody-drug Conjugate ZW251 · Zymeworks · phase 1 · NCT07164313
- Dec 31, 2028GPC3-targeted Plasmid DNA Vaccine NWRD06 · Newish Biotech (Wuxi) · phase 2 · NCT07324304
- Jul 31, 2029Actinium Ac 225 GPC3-targeted Antibody Conjugate BAY 3547926 · Bayer · phase 1 · NCT06764316
- May 2030ACE723 · Acepodia Biotech · phase 1 · NCT07861425
- Jun 2030Actinium Ac 225 GPC3-targeted Peptide RYZ801 · Bristol-Myers Squibb · phase 2 · NCT06726161
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.